FATTY ACIDS IN INFANT FORMULA APPROVED

The FDA has approved two controversial fatty acids in a preterm infant formula. Found naturally in breast milk and added to full-term infant formulas, docosahexanoic (DHA) and arachidonic acid (ARA) may improve infantsî brain and vision development. The newly approved Enfamil Premature LIPL, which contains DHA and ARA, will be available later this month, said Mead Johnson, makers of the formula.

The fatty acids are controversial because studies have found various results in their effectiveness. The latest study in Julyís Pediatrics found no significant benefits on developmental outcomes in preterm infants fed formula supplemental with DHA and ARA as compared to those without the additional ingredients (1). At 18 months, the infants who received the DHA- and ARA- rich formula were shorter in height than control formula-fed infants as well as breast-fed infants. The researchers call for further investigation to include developmental tests and growth measurements beyond the parameter of 18 months of age.

Go to www.pediatrics.org/current.shtml for the abstract.

Reference: 1. Fewtrell MS, Morley R, Abbott RA, et al. Double-blind, randomized trial of long-chain polyunsaturated fatty acid supplementation in formula fed to preterm infants. Pediatrics.2002 July; 110 (1 Pt 1):73-82

Source: Nutrition Week;XXXII:14; July 22,2002; p.6

health facts  |  in the news  |  featured stories  |  events  |  about us  |  resources

Click here to send this page   © 2009 AACHAC.ORG. All rights reserved.

The African American Community Health Advisory Committee
A partnership with Mills-Peninsula Health Services